Octozi has raised $3 million in seed funding led by Surface Ventures, with Remarkable Ventures joining, adding to an earlier, undisclosed investment from Debiopharm’s venture arm.
The New York company’s founder built the case for the round on Swiss pharma backing and a Roche presentation in Basel.
A peer-reviewed study found that the platform’s AI assistance increased data-cleaning throughput by 6.03-fold and could save $5.1 million on a representative Phase III oncology trial.
Amit Patel worked for years on products at Google and Meta, including a security project at Google X that Google later brought back in-house. When he started his own company, he decided not to build another enterprise SaaS business. Instead, he used what he learned from his family of doctors and relatives who work in clinical trials.
“That kind of process still relies heavily on people, contract research organisations, and spreadsheets,” Patel tells Tech Funding News. He points out that clinical development is still the main part of drug discovery, where AI is not widely used.
